| Charles L Backus, DO | |
|
273 Highway 11 E, Bulls Gap, TN 37711-3433 | |
| (423) 393-4146 | |
| (423) 393-4377 |
| Full Name | Charles L Backus |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 273 Highway 11 E, Bulls Gap, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801856414 | NPI | - | NPPES |
| 3300057 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083A0300X | Preventive Medicine - Addiction Medicine | 1551 (Tennessee) | Secondary |
| 207P00000X | Emergency Medicine | DO1551 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emmaus Medical And Counseling | 1153673389 | 3 |
| Emmaus Medical And Counseling | 1153673389 | 3 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago
| Entity Name | Emmaus Community Healthcare, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356379093 PECOS PAC ID: 3870560741 Enrollment ID: O20040911000150 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago
| Entity Name | Northeast Tennessee Emergency Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467427138 PECOS PAC ID: 7517911712 Enrollment ID: O20050310000431 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago
| Entity Name | Appalachian Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689985863 PECOS PAC ID: 6901099639 Enrollment ID: O20101026000515 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago
| Entity Name | Health Express |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417352618 PECOS PAC ID: 5799072963 Enrollment ID: O20161003001785 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago
| Entity Name | Emmaus Medical And Counseling |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598256117 PECOS PAC ID: 1153673389 Enrollment ID: O20181016002174 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles L Backus, DO 2514 Wesley St, Suite 104, Johnson City, TN 37601-1764 Ph: (423) 833-5547 | Charles L Backus, DO 273 Highway 11 E, Bulls Gap, TN 37711-3433 Ph: (423) 393-4146 |
News Archive
Boston Scientific Corporation today announced the launch of its new Kinetix™ Guidewire for use in percutaneous coronary intervention (PCI) procedures. Guidewires are small flexible wires physicians use to deliver interventional devices such as drug-eluting stents. The Kinetix Guidewire features a unique micro-cut nitinol sleeve designed for significantly improved torque control compared to conventional spring coil guidewires.
Base editing is a novel gene editing approach that can precisely change individual building blocks in a DNA sequence.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
House Speaker Nancy Pelosi's record of passing all the bills she has brought forward - despite opponents' caricature of her as inept - mean that the health public option remains viable in the House and the House-Senate conference, says ex-White House staffer and former House Aging Committee and Health Subcommittee Chief of Staff Robert Weiner. Pelosi told Weiner, "We will not be deterred. We will pass the bill."
› Verified 9 days ago